Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Terminated × Doxorubicin × Clear all

Phase

Phase 2 71 Phase 3 24 Phase 1/2 16 Phase 1 15 Phase NA 2 Phase EARLY_PHASE1 2 Phase 2/3 2 Phase 4 1

Status

Completed 11 Unknown 5 Withdrawn 1 Terminated 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Sodium Chloride 4 Saline Solution 4 Pregabalin 4 Ketamine 4 Fentanyl 4 Bevacizumab 4 Tranexamic Acid 3 Photochemotherapy 3 Metformin 3 Letrozole 3 Docetaxel 3 Cyclophosphamide 3 ulipristal acetate 2 sodium glycididazole 2 nilotinib 2 liposomal doxorubicin 2 human papillomavirus vaccine, L1 type 16, 18 2 fludarabine 2 fluciclovine F-18 2 epoetin beta 2 aldesleukin 2 Trastuzumab 2 Surveys and Questionnaires 2 Sorafenib 2 Sofosbuvir 2 Rituximab 2 Ribavirin 2 Pemetrexed 2 Paclitaxel 2 Methotrexate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02688803 2025-12-04

OTT15-04

Ottawa Hospital Research Institute

Phase 4 Terminated

2 enrolled 4 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡